NCT05863819View on ClinicalTrials.gov

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

March 30, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

February 1, 2027

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
OTHER

No Intervention

As this is an observational study, no intervention will be administered in this study.

Trial Locations (1)

200032

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, P. R. China, Shanghai

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY